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Abstract Myosin binding protein C is a protein of the myosin
filaments of striated muscle which is expressed in isoforms
specific for cardiac and skeletal muscle. The cardiac isoform is
phosphorylated rapidly upon adrenergic stimulation of myocar-
dium by cAMP-dependent protein kinase, and together with the
phosphorylation of troponin-I and phospholamban contributes to
the positive inotropy that results from adrenergic stimulation of
the heart. Cardiac myosin binding protein C is phosphorylated by
cAMP-dependent protein kinase on three sites in a myosin
binding protein C specific N-terminal domain which binds to
myosin-S2. This interaction with myosin close to the motor
domain is likely to mediate the regulatory function of the protein.
Cardiac myosin binding protein C is a common target gene of
familial hypertrophic cardiomyopathy and most mutations
encode N-terminal subfragments of myosin binding protein C.
The understanding of the signalling interactions of the
N-terminal region is therefore important for understanding the
pathophysiology of myosin binding protein C associated
cardiomyopathy. We demonstrate here by cosedimentation
assays and isothermal titration calorimetry that the myosin-S2
binding properties of the myosin binding protein C motif are
abolished by cAMP-dependent protein kinase-mediated tris-
phosphorylation, decreasing the S2 affinity from a Kd ofW5 WM
to undetectable levels. We show that the slow and fast skeletal
muscle isoforms are no cAMP-dependent protein kinase
substrates and that the S2 interaction of these myosin binding
protein C isoforms is therefore constitutively on. The regulation
of cardiac contractility by myosin binding protein C therefore
appears to be a ‘brake-off’ mechanism that will free a specific
subset of myosin heads from sterical constraints imposed by the
binding to the myosin binding protein C motif.
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1. Introduction
Myosin binding protein C (MyBP-C) is a modular muscle
protein of the intracellular immunoglobulin superfamily (re-
viewed in [1]) which is expressed in at least three isoforms, its
cardiac isoform being strictly speci¢c for heart muscle in
mammals [2,3]. The C-terminal region interacts with the light
meromyosin portion (LMM) of myosin as well as with titin,
thus anchoring the protein to the thick ¢lament shaft and
specifying its sarcomeric localization [1]. MyBP-C is localized
to the central region of the thick ¢lament (C-zone) in regular
stripes spaced 43 nm apart [4^6]. There are 11 C-zone stripes.
However, in mammalian muscle, only stripes 3^11 are usually
occupied by MyBP-C, stripe 3 can also be occupied by MyBP-
H. The proteins of stripes 1 and 2 are unknown. Due to the 43
nm spacing, only every third level of myosin heads in the C-
zone associated with a MyBP-C molecule [4] and the function
of the protein may involve cooperative changes over larger
distances. Furthermore, the localization of MyBP-C to the
central region of the thick ¢lament implies that its unknown
regulatory functions can only a¡ect myosin heads when the
overlap of actin and myosin ¢laments extends into the C-zone.
The presence of the protein may therefore help to sense the
degree of actomyosin overlap.
Cardiac MyBP-C is phosphorylated in a dynamic way by
cAMP-dependent protein kinase (cAPK), suggesting a role in
the L-adrenergic regulation of muscle contraction [7^12].
Phosphorylation occurs on three sites in a MyBP-C-speci¢c
domain in the N-terminal region, the MyBP-C motif [12]. This
region is highly conserved between all isoforms of MyBP-C
and between species [12,13]. The high degree of sequence iden-
tity and cross-species conservation between various MyBP-C
isoforms suggests that the function of the MyBP-C motif is
speci¢ed by the conserved regions and that the three phos-
phorylation sites found experimentally in the cardiac isoform
represent an additional feature. We could show recently that
the MyBP-C motif binds to the proximal 126 residues of the
myosin-S2 segment, close to the lever-arm domain of the my-
osin head [13]. This segment of myosin-S2 is almost com-
pletely identical between all sarcomeric myosin isoforms and
vertebrate species [13]. The interaction with MyBP-C is hence
independent of the MyBP-C or myosin isoform and the
MyBP-C motifs of both cardiac as well as slow skeletal
MyBP-C were demonstrated experimentally to bind to the
N-terminal S2 segment with comparable a⁄nities [13]. The
interaction with S2 directs the A-band association of N-ter-
minal cardiac MyBP-C fragments in neonatal rat cardiomyo-
cytes [13,14]. It has been proposed that the interaction with
myosin-S2 could modulate the head-tail motility of the two-
headed sarcomeric myosin [13], based on the observation that
antibody Fab-fragments against the same region of S2 con-
strain the movement of the myosin heads [15]. The control of
such a constraint by phosphorylation of MyBP-C might there-
fore release this ‘brake’ and recruit myosin heads for active
force production, possibly in a cooperative way along several
crowns of myosin heads.
MyBP-C has been shown to be one major protein involved
in the pathophysiology of familial hypertrophic cardiomyop-
athy [1]. However, its physiological role is still poorly under-
stood. Most MyBP-C mutations that cause FHC are pre-
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dicted to result in N-terminal fragments of the protein [1].
Therefore, the e¡ect of cardiac MyBP-C phosphorylation on
the interaction with myosin-S2 is of great importance to
understand the basis of the regulatory mechanism of this pro-
tein and to gain insight into possible pathological mechanisms
in FHC.
2. Materials and methods
2.1. Bu¡ers
Bu¡er A (myosin mini¢laments): Tris-citrate pH 8.0 10 mM. Bu¡er
B (cosedimentation assay): Tris-HCl pH 7.0 20 mM, NaCl 200 mM,
DTE 1 mM, EDTA 1 mM. Bu¡er C (isothermal titration calorimetry
(ITC)): MES/NaOH pH 7.0 20 mM, NaCl 50 mM, DTE 1 mM,
EDTA 1 mM)
2.2. Protein expression, puri¢cation and phosphorylation
MyBP-C and L-myosin-S2 fragments were expressed soluble as de-
scribed [12,13,16] using the pET expression system [17]. His6-tagged
proteins were puri¢ed on Ni2 NTA columns following the manufac-
turer’s instructions (Qiagen, Germany) and further puri¢ed by anion
exchange chromatography on a monoQ column (Pharmacia, Sweden).
The His6 tag was cleaved o¡ by recombinant TEV protease (Gibco
BRL, UK). Myosin (rabbit, skeletal) was prepared according to the
method of [18]. Myosin mini¢laments were prepared as described [19]
from myosin which was previously puri¢ed by three cycles of high-
and low salt precipitation. The content of endogeneous MyBP-C after
this scheme was estimated by Western blotting using a speci¢c MyBP-
C antibody [3] and by gel densitometry to be below 5%.
Preparative phosphorylation of cardiac C1C2 (c-C1C2) was carried
out in a volume of 10 ml at a concentration of 1 mg/ml c-C1C2,
100 U/ml bovine brain cAPK catalytic subunit (Sigma, Germany)
and 0.7 mM ATP in 20 mM HEPES pH 7.0, 5 mM MgCl2, 1 mM
dithiothreitol at 25‡C. Samples of 5 Wl were taken at regular intervals
and the degree of phosphorylation was monitored by mass spectrom-
etry. Complete tris-phosphorylation was observed after about 3 h.
2.3. Cosedimentation assay
All proteins (except myosin mini¢laments) were dialyzed into bu¡er
B and centrifuged prior to use at 4‡C for 30 min at 400 000Ug using a
Beckman TLA 100.1 rotor and an Optima TL ultracentrifuge. Appro-
priate amounts were mixed in Beckman polycarbonate centrifuge
tubes (number 343776) and the volume was made up to 25 Wl with
bu¡er B. Myosin mini¢laments (25 Wl of 5 WM in bu¡er A) were
added to the mixture to give a ¢nal volume of 50 Wl, pH 7.3, and a
NaCl concentration of 100 mM. The mixture was incubated at 4‡C
for 30 min and subsequently centrifuged for 20 min at 400 000Ug.
The supernatant was removed and the pellet was washed twice with
100 Wl of a 1:1 mixture of bu¡er A and bu¡er B. The pellet was
redissolved in 50 Wl of 7 M urea and appropriate amounts of super-
natant and pellet were analyzed by SDS-PAGE as described [20]. Gels
were stained for 24 h in staining solution (1.5% w/v Coomassie bril-
liant blue R250, 40% ethanol, 10% acetic acid) and subsequently de-
stained for 48 h.
2.4. ITC
All proteins were dialyzed into bu¡er C and centrifuged at
100 000Ug for 10 min immediately prior to use. Calorimetric experi-
ments were carried out using a titration calorimeter from Microcal,
USA, with a 250 Wl injection syringe while stirring at 400 rpm. The
concentrations of the myosin-S2 constructs in the syringe were gen-
erally 10^20 times higher than the C1C2 concentrations in the reac-
tion cell. The reference cell was ¢lled with 1 mM sodium azide. An
initial injection was performed with a small volume of 0.25 times the
experimental injection volume (5^10 Wl). Data analysis was performed
with the manufacturer’s software. Experimental values for the binding
constant, heat of binding and stoichiometric ratio are from deconvo-
lution using non-linear least-squares minimization. The heats of dilu-
tion were determined in independent experiments and subtracted from
the raw data prior to data analysis.
2.5. Mass spectrometry
Nano-electrospray mass spectroscopy was performed with a Finni-
gan LCQ mass spectrometer equipped with a micromanipulator for
the correct positioning of the nanospray needle. The needles and the
ion source were made following the original design of Mann et al.
[21]. In short, capillaries (GC120F from Clark Instruments, Reading,
UK) were pulled using the DMZ-Universal puller (Zeitz-Instrumente
GmbH, Mu«nchen, Germany). They were coated with gold using a
Polaron SC7610 Sputter Coater (VG Microtech, Uck¢eld, UK) and
a gold target. These needles were ¢lled with 1^4 Wl of aqueous so-
lution and centrifuged for several seconds using a PicoFuge (Tomy
Capsule, Tomy Tech, Palo Alto, CA, USA). The needles were
mounted on the micromanipulator and were carefully brought in con-
tact with the surface of the mass spectrometer. Air pressure was ap-
plied to the needle until a small droplet appeared on the tip. The
needle was then adjusted 2.5 mm opposite to the inlet of the heated
capillary of the mass spectrometer. A potential of 900 V was applied
to the needle and the spectrum was recorded. The original data (i.e.
abundance of the multiple charged protein populations versus mass/
charge) were deconvoluted into mass spectra (relative abundance ver-
sus mass) by means of the deconvolution software BioExplore (Fin-
nigan). The error of the mass spectrometer was 100 ppm in the nor-
mal mass range (150^2000 mu), which was used for all experiments
shown here.
3. Results
3.1. Phosphorylation by cAPK is restricted to the cardiac
isoform of MyBP-C
Phosphorylation by cAPK as well as by an associated cal-
cium-calmodulin-dependent protein kinase is well-documented
for cardiac MyBP-C. We wanted to establish experimentally
whether also the known skeletal isoforms from slow and fast
muscle contain accessible substrate sites for cAPK which are
not evident from multiple sequence comparison [12,13,22]. We
therefore expressed the C1C2 fragments of human fast and
slow skeletal MyBP-C (f-C1C2 and s-C1C2), which contain
the phosphorylatable MyBP-C motif [12], and compared their
substrate properties for cAPK phosphorylation with c-C1C2.
We observed phosphorylation for the c-C1C2 fragment but
not for the two skeletal isoforms (Fig. 1). Quantitative anal-
ysis of the kinetics of c-C1C2 phosphorylation was carried out
by mass spectrometry under preparative conditions. After
2 min of phosphorylation, conversion to the monophospho-
rylated form was visible with no detectable bis- or tris-phos-
Fig. 1. Phosphorylation by cAPK results in phosphate incorporation
into the cardiac MyBP-C motif (lanes 1 and 4), but not the slow
(lanes 2 and 5) or fast (lanes 3 and 6) skeletal isoforms. This dem-
onstrates that adrenergic regulation can act exclusively on the car-
diac isoform. Lanes 1^3: Coomassie-stained gel; Lanes 4^6: autora-
diograph of duplicate. M: marker proteins.
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phorylated protein (Fig. 2A, B). After 90 min, the monophos-
phorylated protein was totally converted to the bis-phos-
phorylated (ca. 20%) and the tris-phosphorylated form (ca.
80%) (Fig. 2C). After ca. 5 h, the reaction was completed
with 100% tris-phosphorylated protein. The sequential ap-
pearance of the three phospho-isoforms of MyBP-C supports
the earlier notion that not all phosphorylation sites in the
MyBP-C motif are equally used and that an ordered hierarchy
of phosphorylation exists [12].
3.2. The cosedimentation of the MyBP-C N-terminal region
with myosin is sensitive to the phosphorylation state of
MyBP-C
We have recently established a cosedimentation assay using
myosin mini¢laments that detects the interaction of the
MyBP-C motif with myosin-S2 [13]. In order to establish
whether tris-phosphorylation of cardiac MyBP-C would in£u-
ence this putative regulatory protein-protein interaction, we
used unphosphorylated and the quantitatively prepared tris-
phosphorylated c-C1C2 in this assay (see Section 2). The un-
phosphorylated c-C1C2 was found to cosediment with myosin
mini¢laments, signifying the binding to the myosin-S2 portion
(Fig. 3). However, tris-phosphorylated c-C1C2 was found to
remain in the supernatant, suggesting that the phosphorylated
protein has a greatly reduced ability to interact with its my-
osin binding site (Fig. 3).
3.3. The binding of cardiac MyBP-C to myosin-S2 is abolished
by cAPK phosphorylation of MyBP-C
For a detailed analysis of the e¡ect of cardiac MyBP-C
phosphorylation on myosin-S2 binding, we used ITC as a
quantitative liquid phase protein interaction assay. Binding
was assayed against the 126 residue S2 fragment S2-v which
contains the MyBP-C binding site. Unphosphorylated c-C1C2
binds to S2-v with a Kd of W5 WM (Fig. 4A) as described
previously [13]. Tris-phosphorylated c-C1C2 was prepared in
the reaction monitored in Fig. 2 and further puri¢ed by Ni-
NTA chromatography to remove excess cAPK and ATP after
the reaction. The titration of S2-v with completely tris-phos-
phorylated c-C1C2 revealed only the heat of dilution of the
protein sample but no speci¢c binding reaction (Fig. 4B), the
titration curve is therefore level. This demonstrates that the
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interaction of c-C1C2 with myosin-S2 is abolished by tris-
phosphorylation or reduced to levels undetectable by ITC or
cosedimentation.
4. Discussion
Regulation of protein-protein interactions by phosphoryla-
tion is a common mechanism to control cell function in eu-
karyotes. Both the response of assembled cellular structures as
well as their assembly itself are regulated by phosphorylation
of speci¢c proteins by dedicated kinases. Sarcomeres, the con-
tractile units of muscle, represent a complex and dynamic
macromolecular assembly that responds to changes in phys-
iological demands on the molecular level. Long-term regula-
tion is achieved by changes in gene expression patterns [23],
whereas short-term dynamic adaptations are mediated by pro-
tein phosphorylation. MyBP-C is one of three proteins rapidly
phosphorylated when myocardium is stimulated by adrenergic
agonists [10]. This stimulation results in an increase in con-
traction force and speed.
We demonstrated recently that the regulatory domain of c-
MyBP-C interacts with a short segment of myosin-S2 close to
the motor domain. This interaction raises the possibility that
the regulation of cardiac contractility by MyBP-C could in-
volve the mobility of the two myosin heads at their head-tail
junction [13]. Recent ultrastructural analysis of phospho-
rylated and unphosphorylated native thick ¢laments suggested
a swinging out of myosin heads concomitant with the phos-
phorylation of cardiac MyBP-C [24,25].
We demonstrate here that the interaction of the N-terminal
regulatory domain of cardiac MyBP-C (MyBP-C motif) with
the myosin-S2 domain is sensitive to cAPK phosphorylation
of the MyBP-C motif. The interaction of both proteins, as
judged from cosedimentation assays and ITC, is regulated in
Fig. 2. Time-course of the sequential phosphorylation of c-C1C2 by cAPK. The control (reaction mixture at 0 min) shows the unphosphoryl-
ated protein (P) with a mass of 34 819 Da and several ion adducts (A). After 2 min incubation, monophosphorylated protein appears (P-P1)
(B). After 90 min, the pools of unphosphorylated and monophosphorylated protein have disappeared and both bis- and tris-phosphorylated
protein (P-P2 and P-P3) are detected (C). After 5.5 h, the reaction led to a complete conversion to tris-phosphorylated protein P-P3).
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an on-o¡ fashion by tris-phosphorylation. It is possible, how-
ever, that in vivo phosphorylation intermediates may occur
which result in a more subtle change in a⁄nity. This on-o¡
regulation suggests that whatever steric constraints would be
imposed by MyBP-C either on the mobility of the myosin
head-tail junction or the swinging out of the myosin head
from the thick ¢lament shaft, would be relieved by MyBP-C
phosphorylation. This could (i) recruit heads for actin binding
and hence force generation or (ii) alter the binding state and
cycling rates of the two-headed myosin. Both mechanisms
would be synergistic to the increased generation of active
force that is achieved by the cAPK-mediated phosphorylation
of sarcomeric proteins in cardiac muscle. The major phos-
phorylation site in cardiac MyBP-C is a cardiac-speci¢c
loop insertion in the MyBP-C motif of the sequence
LAGGGRRIS [12]. Removal of this site restricts the accessi-
bility to the two other cardiac cAPK sites. All three sites are
not found in the skeletal isoform sequences. Since sequence
comparison may overlook physiologically relevant phospho-
rylation sites, we tested the skeletal isoforms of MyBP-C ex-
perimentally for cAPK phosphorylation and found them to be
no substrates. Recent work identi¢ed two phosphorylation
sites for protein kinase C (PKC) in the cardiac MyBP-C motif
[22]. These sites are also not found in the skeletal isoforms.
Furthermore, investigations on intact heart muscle show no
PKC-mediated phosphorylation of MyBP-C under physiolog-
ical conditions [26,27]. Therefore, the selected interaction of
MyBP-C with only few myosin heads must have a ¢bre-type-
dependent modulating e¡ect on contractility independent of
the phosphorylation-dependent on-o¡ switch of this interac-
tion, which is a speci¢c feature of cardiac muscle.
All isoforms of MyBP-C bear a speci¢c sequence at the very
N-terminus which, in the cardiac isoform, comprises a pro-
line-alanine rich stretch and an additional Ig domain [16]. In
addition, a short isoform-speci¢c charged sequence is found in
the MyBP-C motif [13]. The interactions of these regions are
yet unknown. Some sequence homology to the N-terminal
regions of regulatory light chains (not shown) and the spatial
proximity to the myosin light chains suggest that this region
might contribute to isoform-speci¢c regulation possibly in
concert with the regulatory light chain.
It is interesting to note that at least one point mutation in
L-myosin-S2 which causes FHC has an identical net e¡ect on
the interaction of myosin and MyBP-C. The exchange of ly-
sine-924 for glutamate also abolishes their interaction without
a¡ecting the dimeric coiled-coil structure of S2 [13]. Possibly,
Fig. 3. Cosedimentation binding assay of unphosphorylated (lanes
1 and 2) and tris-phosphorylated c-C1C2 (lanes 3 and 4) to myosin
mini¢laments. Supernatants: lanes 1 and 3; pellets: lanes 2 and 4.
Whereas the unphosphorylated control binds to myosin and is
found in the pellet (lane 2), tris-phosphorylated c-C1C2 does not co-
sediment and stays in the supernatant of the reaction (lane 3).
M: marker proteins.
Fig. 4. The binding of c-C1C2 to myosin-S2 is regulated by phos-
phorylation. Isothermal calorimetry demonstrates the liquid phase
interaction of S2-v with C1C2. S2-v is titrated against C1C2 in reg-
ular time intervals and the reaction heat is monitored as a change
of the heating current (Wcal/s, upper panels). Integration of the re-
sulting peaks yields the titration plot (lower panel). (A) 20 WM
c-C1C2 and 350 WM S2-v, (B) 20 WM tris-phosphorylated c-C1C2
and 350 WM S2-v. The experiments demonstrate the interaction of
both proteins in a 1:1 complex in the unphosphorylated state and
yield a dissociation constant of 5.2 WM for the interaction (A). The
binding of both proteins is abolished after tris-phosphorylation of c-
C1C2. only the heat of dilution is detectable (B).
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therefore, some of the FHC-associated mutations in L-myo-
sin-S2 could result in the constitutive mimicry of the phos-
phorylated state of MyBP-C and result in chronic dysregula-
tion of contractility. Indeed, hypercontractility is a feature
observed in several mutations causing FHC [28]. Our results
provide the molecular basis for a functional investigation of
the phosphorylation regulation of cardiac contractility in nor-
mal and diseased heart by the interaction of myosin and
MyBP-C.
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